



OPIE DOCKET NO.: CELL-0317/PA558-USW01
FEB 26 2007
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Timothy John Norman

Confirmation No.: 3724

Application No.: 10/583,642

Group Art Unit: Not Yet Assigned

Filing Date: June 20, 2006

Examiner: Not Yet Assigned

For: BRANCHED MOLECULAR SCAFFOLDS FOR LINKING POLYMER
RESIDUES TO BIOLOGICALLY ACTIVE MOIETIES

DATE OF DEPOSIT: *February 22, 2007*

I HEREBY CERTIFY THAT THIS PAPER IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID,
ON THE DATE INDICATED ABOVE AND IS
ADDRESSED TO THE UNITED STATES PATENT AND
TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA,
VA 22313-1450.

Elizabeth A. McLoud

TYPED NAME: Elizabeth A. McLoud

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:
 - Certification in Accordance with § 1.97(e) is attached; or
 - The fee of \$180.00 as set forth in § 1.17(p) is attached.
- In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).
- Copies of reference numbers 24 - 63 listed on the attached Form PTO-1449 are enclosed herewith.
- Copies of reference numbers 1 - 23 on the attached Form PTO 1449 are not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).
- Copies of references - are not being submitted because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application number , filed for which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.

The relevance of those listed references which are not in the English language is as follows:

There are no listed references which are not in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date: February 22, 2007

Jane Ingles
Jane E. Ingles
Registration No. 48,444

WOODCOCK WASHBURN LLP
Cira Centre
2929 Arch Street, 12th Floor
Philadelphia, PA 19104-2891
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

**Form PTO-1449 Modified**

List of Patent and Publications
Cited by Applicant
(Use several sheets if necessary)

U.S. Department of Commerce
Patent and Trademark Office

Docket No.
CELL-0317/
PA558-USw01

Application No.
10/583,642

Applicant
Timothy John Norman

Filing Date
June 20, 2006

Group
Not Yet Assigned

Confirmation No.
3724

U. S. PATENT DOCUMENTS

Examiner Initial	Document No.	Date	Name	Class	Subclass
1	4,946,778	08/07/90	Ladner, et al.	435	69.6
2	5,219,996	06/15/93	Bodner, et al.	530	387.3
3	5,223,409	06/29/93	Ladner, et al.	435	69.7
4	5,403,484	04/04/95	Ladner, et al.	435	235.1
5	5,427,908	06/27/95	Dower, et al.	435	5
6	5,516,637	05/14/96	Huang, et al.	435	6
7	5,571,698	11/05/96	Ladner, et al.	435	69.7
8	5,580,717	12/03/96	Dower, et al.	435	5
9	5,585,089	12/17/96	Queen, et al.	424	133.1
10	5,658,727	08/19/97	Barbas, et al.	435	6
11	5,677,425	10/14/97	Bodmer, et al.	530	387.1
12	5,698,426	12/15/97	Huse	435	172.3
13	5,733,743	03/31/98	Johnson, et al.	435	69.1
14	5,750,753	05/12/98	Kimae, et al.	556	440
15	5,780,225	07/14/98	Wigler, et al.	435	6
16	5,821,047	10/13/98	Garrard, et al.	435	5
17	5,932,462	08/03/99	Harris, et al.	435	188
18	5,969,108	10/19/99	McCafferty, et al.	530	387.3
19	6,251,382 B1	06/26/01	Greenwald, et al.	424	78.17
20	6,362,254 B2	03/26/02	Harris, et al.	523	406

EXAMINER /Paul Dickinson/

DATE CONSIDERED 04/01/2010

© 2006 WW

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.D./

EXAMINER /Paul Dickinson/

DATE CONSIDERED 04/01/2010

© 2006 WW

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.D./

Form PTO-1449 Modified		Docket No. CELL-0317/ PA558-USw01	Application No. 10/583,642
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Timothy John Norman	
U.S. Department of Commerce Patent and Trademark Office		Filing Date June 20, 2006	Group Not Yet Assigned
		Confirmation No. 3724	

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document No.	Date	Country	Translation	
				YES	NO
24	WO 90/02809 A1	03/22/90	PCT		
25	WO 91/10737 A1	07/25/91	PCT		
26	WO 92/01047 A1	01/23/92	PCT		
27	WO 92/02551 A1	02/20/92	PCT		
28	WO 92/18619 A1	10/29/92	PCT		
29	WO 92/22853 A1	12/23/92	PCT		
30	WO 93/08829 A1	05/13/93	PCT		
31	WO 93/11236 A1	06/10/93	PCT		
32	WO 95/15982 A2	06/15/95	PCT		
33	WO 95/20401 A1	08/03/95	PCT		
34	WO 98/25971 A1	06/18/98	PCT		
35	WO 02/27315 A3	04/04/02	PCT		
36	WO 03/031475 A3	04/17/03	PCT		
37	WO2005/003169 A3	01/13/05	PCT		
38	WO2005/002870 A1	01/13/05	PCT		
39	WO2005/002871 A1	01/13/05	PCT		
40	WO2005/061005 A2	07/07/05	PCT		
41	1 496 076 A1	01/12/05	EP		
42	0 315 450	07/10/29	GB		

EXAMINER /Paul Dickinson/	DATE CONSIDERED 04/01/2010
----------------------------------	-----------------------------------

© 2006 WW

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.D./

EXAMINER /Paul Dickinson/	DATE CONSIDERED 04/01/2010
----------------------------------	-----------------------------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH /P.D./

Form PTO-1449 Modified	Docket No. CELL-0317/ PA558-USw01	Application No. 10/583,642
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)	Applicant Timothy John Norman	
U.S. Department of Commerce Patent and Trademark Office	Filing Date June 20, 2006	Group Not Yet Assigned
	Confirmation No. 3724	

NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

46	Ames, R.S., et al., "Conversion of murine Fab's isolated from a combinatorial phage display library to full length immunoglobulins," <i>J. Immunol. Methods</i> , 1995, 184, 177-186
47	Badcock, J., et al., "A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities," <i>Proc. Natl. Acad. Sci. USA</i> , 1996, 93, 7843-7848
48	Brinkman, U., et al., "Phage display of disulfide-stabilized Fv fragments," <i>J. Immunol. Methods</i> , 1995, 182, 41-50
49	Burton, D.R., et al., "Human antibodies from combinatorial libraries," <i>Advances in Immunology</i> , 1994, 57, 191-280
50	Chapman, A.P., et al., "Therapeutic antibody fragments with prolonged in vivo half-lives," <i>Nature Biotechnology</i> , 1999, 17(8), 780-783
51	Chapman, A.P., "PEGylated antibodies and antibody fragments for improved therapy: a review.", <i>Advanced Drug Delivery Reviews</i> , 2002, 54, 531-545
52	Cole, et al., "The EBV-hybridoma technique and its application to human lung cancer," <i>Monoclonal Antibodies and Cancer Therapy</i> , Alan R. Liss, Inc., 1985, 77-96
53	Greenwald, R.B., et al., "Highly water soluble taxol derivatives: 7-polyethylene glycol carbamates and carbonates," <i>J. Org. Chem.</i> , 1995, 60, 331-336
54	Hurwitz, E., et al., "Inhibition of tumor growth by poly(ethylene glycol) derivatives of anti-ErbB2 antibodies," <i>Cancer Immunology & Immunotherapy</i> , 2000, 49(4-5), 226-234
55	Kettleborough, C.A., et al., "Isolation of tumor cell-specific single-chain Fv from immunized mice using phage-antibody libraries and the re-construction of whole antibodies from these antibody fragments," <i>Eur. J. Immunol.</i> , 1994, 24, 952-958
56	Köhler, G., et al., "Continuous cultures of fused cells secreting antibody of predefined specificity," <i>Nature</i> , 1975, 256, 495-497
57	Kozbor, D., et al., "the production of monoclonal antibodies from human lymphocytes," <i>Immunology Today</i> , 1983, 4, 72-79
58	Mantovani, G., et al., "Design and synthesis of N-maleimido-functionalized hydrophilic polymers via copper mediated living radical polymerization: a suitable alternative to PEGylation chemistry," <i>J. Am. Chem. Soc.</i> , 127(9), 2966-2973 2005
59	Milstein, C., et al., "Hybrid hybridomas and their use in immunohistochemistry," <i>Nature</i> , 1983, 305, 537-539

EXAMINER /Paul Dickinson/**DATE CONSIDERED** 04/01/2010

© 2006 WW

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.D./

EXAMINER	/Paul Dickinson/	DATE CONSIDERED	04/01/2010
-----------------	------------------	------------------------	------------